Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Chikungunya
Biotech
Valneva sells priority review voucher for $103M, R&D to benefit
Vaccine maker Valneva is giving its R&D unit a $103 million gift courtesy of selling an FDA priority review voucher for tropical disease.
James Waldron
Feb 5, 2024 9:15am
FDA delays decision on Valneva's chikungunya vaccine by 3 months
Aug 14, 2023 6:00am
Bavarian Nordic goes 2 for 2 in key chikungunya vaccine trials
Aug 7, 2023 5:40am
Bavarian Nordic chikungunya vaccine hits primary goal in phase 3
Jun 20, 2023 9:00am
Durability of Valneva’s chikungunya vaccine holds up in phase 3
Mar 8, 2022 9:00am
Moderna guides 2 mRNA assets through early clinical tests
Sep 12, 2019 8:45am
